PURPOSE: To determine the natural history of imaging findings seen on magnetic resonance imaging (MRI) of hepatocellular carcinoma (HCC) treated with stereotactic body radiation therapy (SBRT). Although arterial hyperenhancement is a key feature of untreated HCC, our clinical experience suggested that tumors that never progressed could still show hyperenhancement. Therefore, we undertook a systematic study to test the hypothesis that persistent arterial phase hyperenhancement (APHE) after SBRT is an expected finding that does not suggest failure of treatment. METHODS AND MATERIALS: One hundred forty-six patients undergoing SBRT for HCC between January 1, 2007, and December 31, 2015, were screened retrospectively using an institutional review board-approved prospectively maintained registry. Inclusion criteria were (1) HCC treated with SBRT, (2) multiphasic MRI ≤3 months before SBRT, (3) up to 1 year of follow-up MRI post-SBRT, and (4) cirrhosis. The exclusion criterion was ≤3 months of locoregional therapy to the liver segment containing the SBRT-treated HCC. Pre- and post-SBRT MRI from up to 3 years were analyzed in consensus by independent pairs of subspecialty-trained radiologists to determine the temporal evolution of major features for HCC and imaging findings in off-target parenchyma. RESULTS: Sixty-two patients with 67 HCCs (Organ Procurement and Transplantation Network imaging criteria [OPTN] 5a [n = 26], OPTN 5b [n = 28], OPTN 5x [n = 7]; Liver Imaging Reporting Data System [LI-RAD]-M [n = 4] and LiRADs-4 [n = 2]) were studied. Tumor size either decreased (66% [44 of 67]) or remained unchanged (34% [23 of 67]) within the first 12 months. Post-SBRT APHE was common (58% [39 of 67]). When graded using modified Response Evaluation Criteria in Solid Tumors at 3 to 6 months, 25% (17 of 67) met criteria for complete response and 75% (50 of 67) met criteria for stable disease. CONCLUSIONS: SBRT is an effective locoregional treatment option for HCC. Persistent APHE is common and does not necessarily indicate viable neoplasm; thus, standard response assessment such as modified Response Evaluation Criteria should be used with caution, particularly in the early phases after SBRT therapy.
PURPOSE: To determine the natural history of imaging findings seen on magnetic resonance imaging (MRI) of hepatocellular carcinoma (HCC) treated with stereotactic body radiation therapy (SBRT). Although arterial hyperenhancement is a key feature of untreated HCC, our clinical experience suggested that tumors that never progressed could still show hyperenhancement. Therefore, we undertook a systematic study to test the hypothesis that persistent arterial phase hyperenhancement (APHE) after SBRT is an expected finding that does not suggest failure of treatment. METHODS AND MATERIALS: One hundred forty-six patients undergoing SBRT for HCC between January 1, 2007, and December 31, 2015, were screened retrospectively using an institutional review board-approved prospectively maintained registry. Inclusion criteria were (1) HCC treated with SBRT, (2) multiphasic MRI ≤3 months before SBRT, (3) up to 1 year of follow-up MRI post-SBRT, and (4) cirrhosis. The exclusion criterion was ≤3 months of locoregional therapy to the liver segment containing the SBRT-treated HCC. Pre- and post-SBRT MRI from up to 3 years were analyzed in consensus by independent pairs of subspecialty-trained radiologists to determine the temporal evolution of major features for HCC and imaging findings in off-target parenchyma. RESULTS: Sixty-two patients with 67 HCCs (Organ Procurement and Transplantation Network imaging criteria [OPTN] 5a [n = 26], OPTN 5b [n = 28], OPTN 5x [n = 7]; Liver Imaging Reporting Data System [LI-RAD]-M [n = 4] and LiRADs-4 [n = 2]) were studied. Tumor size either decreased (66% [44 of 67]) or remained unchanged (34% [23 of 67]) within the first 12 months. Post-SBRT APHE was common (58% [39 of 67]). When graded using modified Response Evaluation Criteria in Solid Tumors at 3 to 6 months, 25% (17 of 67) met criteria for complete response and 75% (50 of 67) met criteria for stable disease. CONCLUSIONS:SBRT is an effective locoregional treatment option for HCC. Persistent APHE is common and does not necessarily indicate viable neoplasm; thus, standard response assessment such as modified Response Evaluation Criteria should be used with caution, particularly in the early phases after SBRT therapy.
Authors: J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés Journal: J Hepatol Date: 2001-09 Impact factor: 25.083
Authors: C C Olsen; J Welsh; B D Kavanagh; W Franklin; M McCarter; H R Cardenes; L E Gaspar; T E Schefter Journal: Int J Radiat Oncol Biol Phys Date: 2008-11-05 Impact factor: 7.038
Authors: David L Andolino; Cynthia S Johnson; Mary Maluccio; Paul Kwo; A Joseph Tector; Jennifer Zook; Peter A S Johnstone; Higinia R Cardenes Journal: Int J Radiat Oncol Biol Phys Date: 2011-06-07 Impact factor: 7.038
Authors: Alexis Bujold; Christine A Massey; John J Kim; James Brierley; Charles Cho; Rebecca K S Wong; Rob E Dinniwell; Zahra Kassam; Jolie Ringash; Bernard Cummings; Jenna Sykes; Morris Sherman; Jennifer J Knox; Laura A Dawson Journal: J Clin Oncol Date: 2013-04-01 Impact factor: 44.544
Authors: Giovanni Ambrosino; Francesco Polistina; Giorgio Costantin; Paolo Francescon; Rosabianca Guglielmi; Pierluigi Zanco; Franco Casamassima; Antonio Febbraro; Giorgio Gerunda; Franco Lumachi Journal: Anticancer Res Date: 2009-08 Impact factor: 2.480
Authors: Alan W Katz; Sheema Chawla; Zhenhong Qu; Randeep Kashyap; Michael T Milano; Aram F Hezel Journal: Int J Radiat Oncol Biol Phys Date: 2011-12-13 Impact factor: 7.038
Authors: Jung Hyun Kwon; Si Hyun Bae; Ji Yoon Kim; Byung Ock Choi; Hong Seok Jang; Jeong Won Jang; Jong Young Choi; Seung Kew Yoon; Kyu Won Chung Journal: BMC Cancer Date: 2010-09-03 Impact factor: 4.430
Authors: Mishal Mendiratta-Lala; William R Masch; Kimberly Shampain; Andrew Zhang; Alexandria S Jo; Sarah Moorman; Anum Aslam; Katherine E Maturen; Matthew S Davenport Journal: Radiol Imaging Cancer Date: 2020-01-31
Authors: Mishal Mendiratta-Lala; Anum Aslam; Katherine E Maturen; Maria Westerhoff; Chris Maurino; Neehar D Parikh; Yilun Sun; Christopher J Sonnenday; Erica B Stein; Kimberly L Shampain; Ravi K Kaza; Kyle Cuneo; William Masch; Richard Kinh Gian Do; Theodore S Lawrence; Dawn Owen Journal: Int J Radiat Oncol Biol Phys Date: 2021-10-10 Impact factor: 8.013
Authors: Tae-Hyung Kim; Sungmin Woo; Ijin Joo; Mustafa R Bashir; Mi-Suk Park; Lauren M B Burke; Mishal Mendiratta-Lala; Richard K G Do Journal: Abdom Radiol (NY) Date: 2021-05-23
Authors: William C Jackson; Holly E Hartman; Laila A Gharzai; Christopher Maurino; David M Karnak; Mishal Mendiratta-Lala; Neehar D Parikh; Charles S Mayo; Randall K Ten Haken; Matthew J Schipper; Kyle C Cuneo; Theodore S Lawrence Journal: Int J Radiat Oncol Biol Phys Date: 2021-04-18 Impact factor: 8.013